EP Patent

EP3180344B1 — Pyrrolo[2,3-d]pyrimidine derivatives useful for inhibiting janus kinase

Assigned to Pfizer Inc · Expires 2019-09-18 · 7y expired

What this patent protects

Patent listed against chembl-chembl3655081.

Drugs covered by this patent

chembl-chembl3655081 (ABROCITINIB)

Patent Metadata

Patent number: EP3180344B1
Jurisdiction: EP
Classification: —
Expires: 2019-09-18
Drug substance claim: No
Drug product claim: No
Assignee: Pfizer Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.